BioSpace News Archive

Exagen Inc. announced its participation in Investor Summit Group’s Q2 Conference, which takes place May 3rd - 4th, 2022, in New York City at the Westin New York Grand Central Hotel.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the first quarter 2022, after the market close on Wednesday, April 27, 2022.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022.

Quest Diagnostics today announced it has made several organizational changes and leadership appointments of seasoned executives to better support the company’s two-point business strategy to accelerate growth and drive operational excellence.

Outset Medical, Inc. today announced that it will release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022.

Johnson & Johnson will participate in the UBS Global Healthcare Conference on Tuesday, May 24th.

Samsara Vision, today announced FDA approval to initiate a U.S.-based, PMA supplemental study to evaluate improvements in visual acuity and the safety of its SING IMT™ (Smaller-Incision New-Generation Implantable Miniature Telescope) in people living with late-stage AMD.

Ampio Pharmaceuticals, Inc. announced the receipt of written responses from the United States Food and Drug Administration pursuant to a Type C meeting request submitted by the Company earlier in the year regarding the AP-013 trial results.

Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD™ (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six-month follow-up analysis, compared to placebo.

Sight Sciences, Inc. announced that data from clinical studies of the OMNI® Surgical System will be presented at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting.